50,000 Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Pinion Investment Advisors LLC

Pinion Investment Advisors LLC decreased its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 66.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,000 shares of the biotechnology company’s stock after selling 50,000 shares during the period. Pinion Investment Advisors LLC’s holdings in Arrowhead Pharmaceuticals were worth $1,636,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ARWR. Versant Capital Management Inc lifted its position in Arrowhead Pharmaceuticals by 285.1% during the 2nd quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 248 shares during the period. Carolina Wealth Advisors LLC grew its stake in Arrowhead Pharmaceuticals by 80.6% during the 2nd quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 154 shares during the last quarter. Optiver Holding B.V. grew its stake in Arrowhead Pharmaceuticals by 83.8% during the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 186 shares during the last quarter. Persistent Asset Partners Ltd acquired a new position in shares of Arrowhead Pharmaceuticals in the second quarter valued at about $39,000. Finally, Allied Private Wealth LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the second quarter valued at about $43,000. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Analysts Set New Price Targets

ARWR has been the subject of several research analyst reports. UBS Group assumed coverage on Arrowhead Pharmaceuticals in a research note on Thursday, October 15th. They issued a “buy” rating and a $109.00 price objective for the company. B. Riley Financial upped their target price on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Citigroup began coverage on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 8th. They issued a “buy” rating and a $108.00 price target on the stock. JPMorgan Chase & Co. raised their price target on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 17th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 31st. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $99.07.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Michael S. Perry sold 11,600 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the transaction, the director owned 111,459 shares in the company, valued at approximately $9,730,370.70. This represents a 9.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Adeoye Y. Olukotun sold 2,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total transaction of $173,920.00. Following the sale, the director directly owned 31,600 shares in the company, valued at approximately $2,747,936. The trade was a 5.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.60% of the stock is currently owned by company insiders.

Arrowhead Pharmaceuticals Price Performance

NASDAQ:ARWR opened at $49.24 on Tuesday. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. The company has a 50 day moving average price of $66.19 and a 200-day moving average price of $71.39. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $37.06 and a 1-year high of $95.49. The firm has a market cap of $6.94 billion, a price-to-earnings ratio of -21.88 and a beta of 1.34.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues.

The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.

Founded in 1989 as Arrowhead Research Corporation, the company adopted the name Arrowhead Pharmaceuticals in 2015.